Allurion Technologies Inc. executed the non-binding letter of intent to acquire Compute Health Acquisition Corp. (NYSE:CPUH) from Compute Health Sponsor LLC and other in a reverse merger transaction on May 11, 2022. Allurion Technologies Inc. entered into an agreement to acquire Compute Health Acquisition Corp. (NYSE:CPUH) from Compute Health Sponsor LLC and other in a reverse merger transaction for $480 million on February 9, 2023. Allurion Technologies will issue 37.812 million common shares and 9 million as stock contingent payment. Upon closing of the merger, the surviving corporation expects to change its name to ?Allurion Technologies, Inc.? and trade on the New York Stock Exchange under the ticker symbol ?ALUR?. Upon the closing of the proposed transaction, it is expected that the New Company will issue, and assume warrants and other equity incentive arrangements representing or underlying, in the aggregate, 37,812,000 shares of the New Company to Allurion equityholders, with the consideration payable to Allurion equityholders based on an assumed $500 million pro forma enterprise value of the combined New Company. The proposed transaction also includes a minimum cash condition of $70 million (net of certain expenses) and is expected to provide a minimum of $87 million of gross cash proceeds. The proposed transaction will require the approval of the stockholders of each of Compute Health and Allurion and is subject to other customary closing conditions, including the receipt of certain regulatory approvals and a registration statement on Form S-4 (the ?Registration Statement?) being declared effective by the Securities and Exchange Commission (the ?SEC?) including approval of antitrust, registration statement, listing of shares, minimum cash requirement and lock up agreement. The proposed transaction has been approved by the boards of directors of each of Compute Health and Allurion. As of May 2, 2023, the transaction was amended, in connection with the foregoing refinancing transactions, the Company entered into the BCA Amendment with the other Parties, which, among other things, amended the calculation of the aggregate number of shares of Pubco Common Stock to be issued to (or reserved for issuance for) Allurion equityholders upon the consummation of the Intermediate Merger to be as follows: (a) 37,812,000 minus (b) (x) a number of shares of Pubco Common Stock equal to (i) 1,400,000 multiplied by (ii) (x) the aggregate Backstop Purchase Amounts divided by (y) $4 million (such quotient, the ? Backstop Percentage ? and such shares calculated pursuant to this clause (y), the ? BCA Backstop Shares ?); provided that the Backstop Percentage shall not exceed one hundred percent (100%) minus (c) a number of shares of Pubco Common Stock equal to (x) (i) 1,500,000 minus (ii) the BCA Backstop Shares multiplied by (y) the Net Closing Cash Percentage (as defined in the Business Combination Agreement) (such shares, the ? Allocated Shares ?); provided that, if the Backstop Percentage equals one hundred percent (100%), then the Allocated Shares will be a number of shares of Pubco Common Stock equal to greater of (a) the BCA Backstop Shares or (b) 1,500,000 multiplied by the Net Closing Cash Percentage. Additionally, the BCA Amendment replaced the form of Investor Rights Agreement attached as an exhibit to the Existing Business Combination Agreement with a revised form of Investor Rights Agreement and Pursuant to termination letter agreements (each, a ? Termination Agreement ? and, collectively, the ? Termination Agreements ?), entered into by Allurion with each of the Side Letter Holders, the Side Letters were terminated, effective as of May 2, 2023. Compute Health Acquisition shareholder will hold meeting on July 28, 2023 to approve the transaction. Compute Health Acquisition shareholder approved the transaction on July 28, 2023. The proposed transaction is expected to close in the first half of 2023. As of July 28, 2023, the transaction is expected to close on or about August 1, 2023.

Howard.Ellin and Richard.Witzel of Skadden, Arps, Slate, Meagher & Flom acted as legal advisor to Compute Health Acquisition. Danielle M. Lauzon and Paul R. Rosie of Goodwin Procter LLP acted as legal advisor to Allurion Technologies. Jefferies acted as financial advisor to Allurion. Credit Suisse Securities (USA) acted as financial advisor with a service fee of $8 million to Compute Health. On On January 28, 2023, the Company and Credit Suisse agreed to amend the transaction fee in Section 2 of the Arrangement from $8.0 million to $2.0 million. Kirkland & Ellis LLP acted as legal advisor to Jefferies. Derek Dostal and Derek Dostal of Davis Polk & Wardwell LLP acted as legal advisor to Credit Suisse. Dubeck, Matthew B., Glover, Stephen of Gibson, Dunn & Crutcher LLP represented Lincoln International LLC who acted as fairness opinion provider to Compute Health Acquisition Corp. Morrow & Co., LLC acted as information agent and Continental Stock Transfer & Trust Company acted as transfer agent to Compute Health Acquisition.